Drug-Like Antibodies Straight
from Selections

Antibodies selected from our libraries have high affinities and developability properties, as good as, or better, than clinical antibodies on the market, saving you time and money during development.

60% of antibodies selected directly from our Generation 3 libraries have affinities below 10nM; 20% have affinities in the subnanomolar range; and our best affinity antibody to date is 13 pM

After selection we use the machine learning module of AbXtract to group selected antibodies into as many as 1,000 distinctive clusters, providing antibodies against a wide variety of target epitopes

Over 80% of antibodies from our Generation 3 Platform have no measurable biophysical liabilities, with all tested to date behaving as well as, or better, than the best therapeutic antibodies.

To empower discovery at your site, we equip you with our integrated, state-of-the-art, antibody discovery platform, including exclusive libraries, vectors, protocols and extensive training.

All our libraries are provided as exclusive assets, with HCDR3 donors used once and other CDRs reassembled for each library, making the antibody diversity yours alone to mine, and not shared with others.

In addition to in-house designs, we create custom libraries, modifying scaffolds, tags, vectors or excluded liabilities. When you need more hands, let us conduct discovery using your exclusive library.

We use our in-house libraries, integrated selection pipeline, next generation sequencing and AbXtract to generate unusually diverse, high affinity, drug-like, developable antibodies.

Our terms eliminate complexities typically seen in platform transfers. We recognize each company is unique, and have successfully tailored structures to meet each partner’s needs.

Your exclusive HCDR3 diversity can be used to build more than one library format, providing access to different antibody functionalities.